Search

Your search keyword '"Willekens, Christophe"' showing total 191 results

Search Constraints

Start Over You searched for: Author "Willekens, Christophe" Remove constraint Author: "Willekens, Christophe" Search Limiters Full Text Remove constraint Search Limiters: Full Text
191 results on '"Willekens, Christophe"'

Search Results

2. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

3. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

4. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

5. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes

6. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

7. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

8. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

9. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

10. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

11. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

13. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

14. Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

16. Coopération entre les mutations Jak2 V617F et Srsf2 P95Hdans le système hématopoïétique

17. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

18. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

19. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

20. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening

24. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

25. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

26. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

27. Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

28. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset

29. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.

30. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

31. Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report

32. ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

33. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

34. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

35. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

36. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

37. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines

38. Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

39. Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

40. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

41. Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

42. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

43. Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

44. Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

46. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

47. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

48. AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

49. Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study

50. A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience

Catalog

Books, media, physical & digital resources